Acute effects of medetomidine, a selective alpha 2-adrenoceptor agonist, on anterior pituitary hormone and cortisol secretion in man

Acta Endocrinol (Copenh). 1988 Sep;119(1):11-5. doi: 10.1530/acta.0.1190011.

Abstract

Single iv doses (25, 50 and 100 micrograms) of medetomidine, a selective alpha 2-adrenoceptor agonist of the imidazole type, were administered to 8 healthy male volunteers in a randomized, double-blind, placebo-controlled study. The concentration of hGH in plasma was powerfully and dose-dependently increased. The plasma level of cortisol was dose-dependently decreased, whereas TSH showed a slight but statistically significant increase. Plasma levels of PRL, FSH and LH were unaffected by the drug. Medetomidine appears to resemble other alpha 2-adrenoceptor agonists, notably clonidine, in its endocrine effects. Its high selectivity and short duration of action make it a suitable tool for studies of the physiology and pharmacology of alpha 2-adrenoceptors in man.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adrenergic alpha-Agonists / administration & dosage*
  • Adult
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Follicle Stimulating Hormone / blood
  • Growth Hormone / blood
  • Humans
  • Hydrocortisone / blood
  • Hydrocortisone / metabolism*
  • Imidazoles / administration & dosage*
  • Luteinizing Hormone / blood
  • Male
  • Medetomidine
  • Pituitary Hormones, Anterior / blood
  • Pituitary Hormones, Anterior / metabolism*
  • Prolactin / blood
  • Random Allocation
  • Thyrotropin / blood

Substances

  • Adrenergic alpha-Agonists
  • Imidazoles
  • Pituitary Hormones, Anterior
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Thyrotropin
  • Growth Hormone
  • Medetomidine
  • Hydrocortisone